A Guide to Filtration Sterilization, From Microbial Retention Testing to Custom Validations

Summary: This Pharma Matters Q&A touches on a key component of sterile manufacturing.

Sterilization by filtration is a critical step in the manufacturing of sterile pharmaceutical products. As described by Nelson Laboratories, this process assures sterility by physically removing microorganisms from the fluid stream.

Importantly, proper filtration sterilization causes no adverse effects to product quality. It is especially important in dealing with thermally sensitive products.

In this Pharma Matters Q&A, Tonya Morris, Nelson Labs Global Segment Director, Pharmaceutical Microbiology, contributes an overview of filtration sterilization in aseptic processing. She and Isabel Vance, Nelson Labs Study Director III, then address certain key quality attributes. Among these are microbial retention and the testing that validates this.

Morris and Vance also look at the regulatory side of the process, and how it has changed over time. But first: A definition of when filtration sterilization is appropriate, and under what conditions to perform it.

A Summary

Contract Pharma: Contextualize the critical nature of filtration sterilization in aseptic pharmaceutical processing. How does this impact product safety?

Tonya Morris: Filtration sterilization is used for products that cannot undergo terminal sterilization. This can be due to several factors: heat sensitivity, structural fragility, or complex formulations. Before selecting filtration as the sterilization method, manufacturers should make a thorough and well‑documented effort to determine whether terminal sterilization is feasible. Only when terminal sterilization is demonstrably unsuitable should filtration be adopted.

Once selected, filtration sterilization must be recognized as one of the most significant critical control points in aseptic processing. It represents the final sterility assurance step prior to packaging, making it a decisive barrier against microbial contamination. Because there is no subsequent microbial inactivation (kill) step, the performance of the sterilizing filter directly determines the sterility and safety of the finished product.

For this reason, regulation of filtration sterilization across pharmaceutical, biologic, and healthcare product manufacturing is tight. A failure at this stage is catastrophic, as it compromises the entire batch and poses direct patient safety risks. By removing microorganisms and particulates immediately before filling, filter sterilization safeguards product quality. This also ensures aseptically processed products remain sterile without altering their chemical or biological integrity.

Importance of Microbial Retention Testing

CP: What are some of the key reasons why microbial—particularly bacterial—retention testing is such a crucial component of filter validation?

Morris, Isabel Vance: Microbial retention testing is one of the most demanding and critical elements of sterilizing filter validation. It provides direct, demonstrable evidence that a filter can reliably remove microorganisms under worst-case, product-, and process-specific conditions.

This testing confirms that a filter meets “sterilizing-grade” performance by challenging it under the most stringent conditions relevant to a manufacturer’s process, including the use of an appropriate challenge organism. In doing so, it goes beyond nominal pore size ratings to verify actual in-use performance.

Additionally, microbial retention testing is essential for regulatory compliance, generating the data required to meet expectations from agencies such as the FDA, EMA, and PIC/S. Manufacturers often use the results to define critical process parameters, including maximum allowable filtration volumes as well as acceptable pressure and flow rate limits. Microbial retention testing serves as the only direct demonstration that a sterilizing-grade filter can consistently perform its intended function under real-world, product-specific, worst-case conditions. That makes it a critical control point for both process validation and patient safety assurance.

CP: Either the filter manufacturer or the user can perform these tests. What are some things to watch out for with each of these approaches?

Morris: Manufacturer microbial retention and performance data provide a baseline. Each are produced using standardized, highly controlled test conditions and well‑characterized challenge systems. However, these data do not always capture the full range of process specific variables, such as product composition, viscosity, surfactant content, pressure profiles, or filtration volumes. These can influence microbial retention in an actual manufacturing environment.

Conversely, user-executed validation studies enable direct assessment of filter performance under true worst‑case, process‑specific conditions. However, they require substantial technical capability, appropriate biosafety infrastructure, and rigorous documentation to meet regulatory expectations. We recommend a combined approach, using manufacturer data as well as targeted, process-specific studies for confirmation. This frequently proves to be a reliable strategy to ensure both filter performance and product safety.

Knowledge is Power

CP: There are standards for each of these types of testing. Are there nuances in the regulations that have changed over time? What do testers most commonly overlook?

Morris: Regulatory expectations for filter validation have evolved toward a more risk-based and process-specific approach. While established standards and guidance documents remain foundational, agencies increasingly expect manufacturers to demonstrate that testing reflects actual process conditions, rather than relying solely on generic or historical data.

Filter validation should be considered as part of the broader contamination control strategy. Regulators are expecting a holistic view, and filtration is just one element in a comprehensive sterility assurance program. It should not be a standalone control.

CP: What’s the importance of knowing the bioburden of your solution, relative to selecting a suitable challenge organism?

Morris and Vance: Understanding the bioburden of a solution is essential for selecting a challenge organism that appropriately reflects worst-case conditions. The naturally occurring microorganisms present in a process may differ in size, morphology, and resistance from standard test organisms, which can influence filter performance. By characterizing the bioburden, manufacturers can better assess if standard challenge organisms are sufficiently conservative. Or, they can evaluate the need for additional studies. This ensures that validation testing is both scientifically justified and relevant to actual manufacturing risks. Aligning the challenge organism with process-specific bioburden strengthens the credibility of validation data and supports a more robust sterility assurance strategy.

Final Thoughts

CP: Briefly talk us through designing a custom bacterial retention validation. When would this be most appropriate and what are some key tips to remember?

Morris and Vance: Custom bacterial retention validations are most appropriate when standard validation approaches may not sufficiently represent the actual process—for example, with complex formulations, high-viscosity solutions, or products that are antagonistic to the organism. In these cases, modification may be more appropriate in order to demonstrate that the filter is suitable for use.

Regulatory bodies prefer direct inoculation of the challenge organism as the preferred method. However, that is only if the organism can survive, not just in the drug formulation, but also within the process parameters. Designing a custom study begins with identifying worst-case process conditions, including maximum pressure, flow rate, production time, and product characteristics. Next comes a suitability test, to determine whether the challenge organism can survive a direct inoculation into the product. The suitability test incorporates the drug product, production time, and the temperature during processing. If the organism is unable to survive, then modifications to the test procedure will be made. Some modifications might include a reduced exposure time, removing the antagonistic component from the product, or a two-part filtration with the product and then the challenge organism in a placebo product, among others.

Whatever the modifications, the study should incorporate appropriate controls and conditions that closely mimic or exceed real manufacturing parameters. When executed properly, custom validation provides strong, process-specific evidence of filter performance and can significantly strengthen regulatory submissions.